30,550 Illumina, Inc. $ILMN Shares Purchased by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 3,405.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,447 shares of the life sciences company’s stock after purchasing an additional 30,550 shares during the period. Fulcrum Asset Management LLP’s holdings in Illumina were worth $8,554,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ILMN. BlackRock Inc. purchased a new position in Illumina during the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC raised its position in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new stake in Illumina in the 2nd quarter worth approximately $617,981,000. Janus Henderson Group PLC lifted its holdings in Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after buying an additional 29,094 shares during the period. Finally, Southpoint Capital Advisors LP lifted its holdings in Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock worth $258,846,000 after buying an additional 349,536 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

ILMN stock opened at $213.13 on Monday. Illumina, Inc. has a 1 year low of $112.65 and a 1 year high of $309.35. The company has a market cap of $32.23 billion, a P/E ratio of 36.68, a PEG ratio of 2.89 and a beta of 1.46. The firm has a 50-day moving average of $249.15 and a 200 day moving average of $178.12. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.43 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Guggenheim lifted their price objective on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. JPMorgan Chase & Co. decreased their target price on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a report on Friday, October 30th. Weiss Ratings upgraded Illumina from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. Stifel Nicolaus raised their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup lifted their price target on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a report on Monday, November 2nd. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $244.24.

Insider Activity

In other news, Director Keith Meister sold 299,336 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the transaction, the director owned 1,409,851 shares in the company, valued at $307,291,123.96. This trade represents a 17.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 1,601,541 shares of company stock valued at $354,755,291. 2.90% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data.

The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers internationally.